Ongoing Clinical Trials for Supraventricular Arrhythmia
This article provides information about 2 ongoing clinical trials focused on supraventricular arrhythmia, specifically atrial fibrillation and atrial arrhythmia. These studies are investigating different medications to help manage irregular heartbeats and improve heart rhythm in patients with these conditions. Trials are currently taking place in the Netherlands and France.
Clinical trial locations
- France
- Netherlands
Study on Semaglutide for Achieving Sinus Rhythm in Patients with Obesity and Persistent Atrial Fibrillation
This trial is investigating whether Semaglutide can help restore a normal heart rhythm in people who have both obesity and persistent atrial fibrillation. Atrial fibrillation is a condition where the heart beats irregularly, which can lead to various complications including poor blood flow and increased risk of blood clots.
Who can participate: You may be eligible if you are 18 years or older and have symptomatic, first-detected persistent atrial fibrillation that was noticed for the first time within the past 6 months. You must also have obesity, which means a Body Mass Index of 30 or higher, or a BMI of 27 or higher if you have other weight-related health issues like high blood pressure, high cholesterol, sleep problems, or heart disease. You need to be scheduled for electrical cardioversion, a procedure to help restore normal heart rhythm, and must provide written informed consent.
Who cannot participate: The study excludes patients who do not have obesity or atrial fibrillation. You also cannot join if you are outside the specified age range or if you are part of a vulnerable population that may need special protection or care.
What the trial involves: Participants receive either Semaglutide or a placebo as a weekly injection under the skin for one year. Semaglutide is a medication that helps control weight by mimicking a hormone called GLP-1, which regulates appetite and insulin levels. Throughout the study, researchers monitor changes in heart rhythm, symptoms of atrial fibrillation, quality of life, weight, blood pressure, cholesterol levels, and the number of hospital visits. The main goal is to see if Semaglutide can help patients achieve and maintain a normal heart rhythm while also addressing obesity-related health issues.
Study on Flecainide to Reduce Risk of Atrial Arrhythmia After Patent Foramen Ovale Closure in Patients
This trial examines whether Flecainide can prevent irregular heartbeats in patients who have undergone a procedure to close a patent foramen ovale (PFO), which is a small opening in the heart that didn’t close naturally after birth. Sometimes after this closure procedure, patients can develop atrial arrhythmias or tachycardia, which are irregular or fast heartbeats.
Who can participate: You may be eligible if you are 18 years or older and are a candidate for PFO closure. The need for this procedure must be confirmed by a team of medical experts. You must be affiliated with Social Security and have provided signed written consent. Additionally, you must have had a successful PFO closure without any major complications.
Who cannot participate: You cannot join this study if you have a history of atrial arrhythmia or tachycardia before the PFO closure procedure. Individuals outside the specified age range and those who are part of vulnerable populations are also excluded.
What the trial involves: After the PFO closure procedure, a small device called an Insertable Cardiac Monitor (ICM) is implanted to continuously track heart activity. Participants then receive Flecainide, an oral medication taken in tablet form, for three months. Flecainide works by blocking sodium channels in the heart, which helps stabilize the heart’s rhythm and is classified as a Class IC antiarrhythmic agent. Researchers monitor participants for six months in total, looking for any episodes of irregular heartbeats (including those with and without symptoms), palpitations, strokes, unexpected medical visits, and any side effects from the medication. The primary focus is on whether Flecainide can reduce the occurrence of atrial arrhythmia during the first three months after the PFO closure.
Summary
These two clinical trials represent different approaches to managing supraventricular arrhythmias. The first study in the Netherlands focuses on addressing atrial fibrillation in patients with obesity using Semaglutide, a medication primarily known for weight management that may also help restore normal heart rhythm. The second trial in France investigates the preventive use of Flecainide, a traditional antiarrhythmic medication, to reduce the risk of irregular heartbeats after a heart procedure.
Both studies use modern monitoring technology to carefully track heart rhythm and assess the effectiveness and safety of their respective treatments. While the trials address different patient populations and use different medications, they share the common goal of improving heart rhythm management and reducing complications associated with atrial arrhythmias.
